NZ-97

• UNSPSC Description:

  NZ-97 is an inhibitor for dipeptidyl peptidase 4 (DPP4) with an IC50 of 18 nM. NZ-97 exhibits a low initial plasma exposure with Cmax of 0.13 µM, which is eliminated in 8 h. NZ-97 ameliorates damage in the Lipopolysaccharides (HY-D1056)-induced lung injury and Bleomycin (HY-108345)-induced lung fibrosis in mice model[1].

• Target Antigen:

  Dipeptidyl Peptidase

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/nz-97.html

• Solubility:

  10 mM in DMSO

• Smiles:

  CCCCCCCCN(C[C@@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O)CC1=CC=C(C=C1)CNC(OCCOC23CC4CC(CC(C4)(C3)[C@@H](C(N5[C@@H](C[C@@H]6C[C@@H]65)C#N)=O)N)C2)=O

• Molecular Weight:

  798.02

• References & Citations:

  [1]Shao S, et al., Pharmacological expansion of type 2 alveolar epithelial cells promotes regenerative lower airway repair. Proc Natl Acad Sci U S A. 2024 Apr 16;121(16):e2400077121.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported